197 related articles for article (PubMed ID: 14982762)
1. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Peytavin G; Isturiz R; Moine P; Rieux V; Cherbuliez C; Péchère JC; Fantin B; Köhler T
Antimicrob Agents Chemother; 2004 Mar; 48(3):765-73. PubMed ID: 14982762
[TBL] [Abstract][Full Text] [Related]
2. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Moine P; Cherbuliez C; Peytavin G; Fantin B; Köhler T
Antimicrob Agents Chemother; 2005 Mar; 49(3):1046-54. PubMed ID: 15728901
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.
Grohs P; Houssaye S; Aubert A; Gutmann L; Varon E
Antimicrob Agents Chemother; 2003 Nov; 47(11):3542-7. PubMed ID: 14576115
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Azoulay-Dupuis E; Mohler J; Bédos JP
Antimicrob Agents Chemother; 2004 Jan; 48(1):80-5. PubMed ID: 14693522
[TBL] [Abstract][Full Text] [Related]
8. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
10. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
11. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
12. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
13. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
15. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Andes D; Craig WA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
18. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
19. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
20. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae.
Johnson CN; Briles DE; Benjamin WH; Hollingshead SK; Waites KB
Emerg Infect Dis; 2005 Jun; 11(6):814-20. PubMed ID: 15963274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]